finn wrote:It is orthodox to think that a hi-end niche drug is always better than a commonly used substance in treating a disease of unknown origin.
It is good to remember that there are two relatively cheap, safe, and oral drugs (minocycline, simvastatin) that are already proven in both pre-clinical and clinical studies to be potentially effective in treating MS.
Unfortunately the retail prize of those drugs is so low that it wouldn't be profitable for manufacturers to conduct large scale clinical trials that are needed to verify drug's efficiency in treating MS.
The MS Society of Canada has already made one serious effort to find a cheaper and more effective drug from outside the "MS-industry". ... One can only wonder why there won't be a larger trial of minocycline in Canada even though the results of the first trial were very impressive. It will be tested in another trial together with Copaxone, but that combination is not oral and cheap any more.
"The Myelin Project staff makes it a point to process requests for experiment funding rapidly-in a matter of weeks, rather than years. ... etc etc etc
finn wrote:It takes a while for me to write these posts, so I don't have the time to argue with you in English. BTW, like we say in Finland: Olet sinä aikamoinen pilkunnussija!
Users browsing this forum: harry1